Kezar Life Sciences, Inc. logo

Kezar Life Sciences, Inc.

Kezar Life Sciences, is a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer.

Kezar Life Sciences was founded by Christopher Kirk, Ph.D., (ex vetern from Onyx Pharma, acquired by Amgen) John Fowler, and Jack Taunton, Ph.D. to discover and develop innovative new therapies targeting protein homeostasis. Kezars lead clinical candidate, KZR-616, a first-in-class selective immunoproteasome inhibitor, is in Ph I/II clinical trials. Kezar is also leveraging its protein secretion pathway platform to discover and develop small molecule therapies targeting cancer and immuno-oncology.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”KZR” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://kezarlifesciences.com
Founded2015
Disease Focus
Development StageClinical
STOCK CODENASDAQ: KZR
Address
300 Utah Avenue, Suite 105,CA,94080,United States
San Francisco
United States
Email
Contact Number
+1 650 822-5600

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Amgen subsidiary Onyx Pharmaceuticals has out licensed intellectual property related to its immunoproteasome program to Kezar, and owns a minority equity interest in the company.

In June 2018, Kezar raised $86.5 Mn through closing of its initial public offering of 5,750,000 shares of its common stock. Earlier in July 2017, Kezar raised $50 Mn in Series B financing round, led by Cormorant Asset Management and Morningside Venture.

In June 2015, Kezar Life Sciences raised $23 Mn in a series A round from Morningside Venture, Cormorant Asset Management, EcoR1 Capital, 9W Capital Management, Omega Funds and Aju IB Investment.